Comparative Outcomes and Safety of Vedolizumab vs Tumor Necrosis Factor Antagonists for Older Adults With Inflammatory Bowel Diseases

IMPORTANCE: Observational comparative effectiveness studies can inform the positioning of biologic therapies for older patients with inflammatory bowel disease (IBD) who are underrepresented in clinical trials. OBJECTIVE: To compare the effectiveness and safety of vedolizumab vs tumor necrosis facto...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Siddharth, Iversen, Aske T., Allin, Kristine H., Jess, Tine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526086/
https://www.ncbi.nlm.nih.gov/pubmed/36178685
http://dx.doi.org/10.1001/jamanetworkopen.2022.34200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526086/
https://www.ncbi.nlm.nih.gov/pubmed/36178685
http://dx.doi.org/10.1001/jamanetworkopen.2022.34200

Ejemplares similares